title: Targeting the Hippo signalling pathway for cancer treatment.
abstract: The Hippo signalling pathway monitors cell-cell contact and external factors that shape tissue structure. In mice, tumourigenesis and developmental abnormalities are common consequences of dysregulated Hippo signalling. Expression of Hippo pathway components is also frequently altered in human tumours and correlates with poor prognosis and reduced patient survival. Thus, the Hippo pathway is an attractive anti-cancer target. Here, we provide an overview of the function and regulation of Hippo signalling components and summarize progress to date on the development of agents able to regulate Hippo signalling for cancer therapy.
authors.affiliation: Division of Molecular and Cellular Biology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.|Division of Cancer Genetics, Medical Institute of Bioregulation Kyushu University, Fukuoka, Japan.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Nakatani
authors.affiliation: Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Maehama
authors.affiliation: Division of Molecular and Cellular Biology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.|Division of Cancer Genetics, Medical Institute of Bioregulation Kyushu University, Fukuoka, Japan.
authors.forename: Miki
authors.initials: M
authors.lastname: Nishio
authors.affiliation: Division of Cancer Genetics, Medical Institute of Bioregulation Kyushu University, Fukuoka, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Goto
authors.affiliation: Division of Cancer Genetics, Medical Institute of Bioregulation Kyushu University, Fukuoka, Japan.
authors.forename: Wakako
authors.initials: W
authors.lastname: Kato
authors.affiliation: Division of Cancer Genetics, Medical Institute of Bioregulation Kyushu University, Fukuoka, Japan.
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Omori
authors.affiliation: Division of Cancer Genetics, Medical Institute of Bioregulation Kyushu University, Fukuoka, Japan.
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Miyachi
authors.affiliation: Division of Molecular and Cellular Biology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
authors.forename: Hideru
authors.initials: H
authors.lastname: Togashi
authors.affiliation: Division of Molecular and Cellular Biology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
authors.forename: Yohei
authors.initials: Y
authors.lastname: Shimono
authors.affiliation: Division of Molecular and Cellular Biology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.|Division of Cancer Genetics, Medical Institute of Bioregulation Kyushu University, Fukuoka, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Suzuki
mesh_terms: D000818:Animals; D000090683:Hippo Signaling Pathway; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D017346:Protein Serine-Threonine Kinases
keywords: Cancer; Hippo; TAZ; Therapy; YAP1